期刊
ANNALS OF HEPATOLOGY
卷 19, 期 3, 页码 320-328出版社
ELSEVIER ESPANA
DOI: 10.1016/j.aohep.2019.11.008
关键词
Metformin; Hypoglycemic agents; Diabetes mellitus, type 2; Carcinoma, hepatocellular; Meta-analysis
资金
- National Natural Science Foundation of China [81660399, 81860423]
- Innovative Research Team Project of Yunnan Province [2015HC033]
- Yunnan Provincial Academician Workstation of Xiaoping Chen [2017IC018]
- Breeding Program for Major Scientific and Technological Achievements of Kunming Medical University [CGYP201607]
- Medical Leading Talent Project of Yunnan Province [L201622]
- Yunnan Provincial Clinical Center of Hepato-biliary-pancreatic Diseases [ZX2019-04-04]
- Leading Academic and Technical Young and Mid-aged Program of Kunming Medical University [60118260108]
- Educational Research and Educational Reform Program of Kunming Medical University [2019-JY-Z-12]
Introduction: This study aimed to compare the therapeutic efficacy of metformin and other anti-hyperglycemic agents in hepatocellular carcinoma (HCC) patients with type 2 diabetes (T2D). Materials: A systematic electronic search on keywords including HCC and different anti-hyperglycemic agents was performed through electronic databases including Medline and EMBASE. The primary outcome was the overall survival (OS). The secondary outcomes were the recurrence-free survival (RFS) and progression-free survival (PFS). Results: Six retrospective cohort studies were included for analysis: Four studies with curative treatment for HCC (618 patients with metformin and 532 patients with other anti-hyperglycemic agents) and two studies with non-curative treatment for HCC (92 patients with metformin and 57 patients with other anti-hyperglycemic agents). Treatment with metformin was associated with significantly longer OS (OR1 yr = 2.62, 95%CI: 1.76-3.90; OR3 yr = 3.14, 95%CI: 2.33-4.24; OR5 yr = 3.31, 95%CI: 2.39-4.59, all P < 0.00001) and RFS (OR1 yr = 2.52, 95%CI: 1.84-3.44; OR3 yr = 2.87, 95%CI: 2.15-3.84; all P < 0.00001; and OR5 yr = 2.26, 95%CI: 0.94-5.45, P = 0.07) rates vs. those of other anti-hyperglycemic agents after curative therapies for HCC. However, both of the two studies reported that following non-curative HCC treatment, there were no significant differences in the OS and PFS rates between the metformin and non-metformin groups (I-2 > 50%). Conclusions: Metformin significantly prolonged the survival of HCC patients with T2D after the curative treatment of HCC. However, the efficacy of metformin needs to be further determined after non-curative therapies for HCC patients with T2D. (c) 2019 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据